US20030036092A1
(en)
*
|
1991-11-15 |
2003-02-20 |
Board Of Regents, The University Of Texas System |
Directed evolution of enzymes and antibodies
|
US5866344A
(en)
*
|
1991-11-15 |
1999-02-02 |
Board Of Regents, The University Of Texas System |
Antibody selection methods using cell surface expressed libraries
|
CN1070533C
(zh)
*
|
1993-02-26 |
2001-09-05 |
三宝乐啤酒株式会社 |
酵母凝集基因及含这些基因的酵母
|
US5766914A
(en)
*
|
1995-01-26 |
1998-06-16 |
Michigan State University |
Method of producing and purifying enzymes
|
AU724621B2
(en)
*
|
1996-01-29 |
2000-09-28 |
Georgetown University |
Amplification of response from expressed recombinant protein
|
US6699658B1
(en)
|
1996-05-31 |
2004-03-02 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
US6696251B1
(en)
|
1996-05-31 |
2004-02-24 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
US6300065B1
(en)
|
1996-05-31 |
2001-10-09 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
EP0879878A1
(en)
*
|
1997-05-23 |
1998-11-25 |
Quest International B.V. |
Beer and similar light-sensitive beverages with increased flavour stability and process for producing them
|
EP0916726A1
(en)
|
1997-11-13 |
1999-05-19 |
Rijksuniversiteit te Groningen |
Attaching substances to micro-organisms
|
US6759243B2
(en)
|
1998-01-20 |
2004-07-06 |
Board Of Trustees Of The University Of Illinois |
High affinity TCR proteins and methods
|
ATE535154T1
(de)
|
1998-03-12 |
2011-12-15 |
Vhsquared Ltd |
Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
|
EP0954978B1
(en)
|
1998-03-12 |
2011-11-30 |
VHsquared Limited |
New products comprising inactivated yeasts or moulds provided with active antibodies
|
US7060669B1
(en)
|
1999-03-25 |
2006-06-13 |
Valtion Teknillinen Tutkimuskeskus |
Process for partitioning of proteins
|
US7132273B1
(en)
|
2000-07-26 |
2006-11-07 |
Korea Research Institute Of Bioscience And Biotechnology |
Cell wall anchor proteins derived from yeast, genes thereof and cell surface expression systems using the same
|
WO2002046400A2
(en)
*
|
2000-12-08 |
2002-06-13 |
The Board Of Trustees Of The University Of Illinois |
Mutated class ii major histocompatibility proteins
|
WO2002048193A2
(en)
*
|
2000-12-13 |
2002-06-20 |
Unilever N.V. |
Camelidae antibody arrays
|
KR100714670B1
(ko)
*
|
2001-04-19 |
2007-05-07 |
간사이가가쿠기카이세이사쿠가부시키가이샤 |
세포 표층 결합 단백질 및 이의 용도
|
EP1395648B1
(en)
|
2001-06-11 |
2009-04-22 |
Applied NanoSystems B.V. |
Methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms
|
US20030186374A1
(en)
|
2001-10-01 |
2003-10-02 |
Hufton Simon E. |
Multi-chain eukaryotic display vectors and uses thereof
|
WO2003064608A2
(en)
*
|
2002-01-25 |
2003-08-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Surface based translation system
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US7563600B2
(en)
|
2002-09-12 |
2009-07-21 |
Combimatrix Corporation |
Microarray synthesis and assembly of gene-length polynucleotides
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
DK2330201T3
(en)
|
2003-10-22 |
2017-07-24 |
Keck Graduate Inst |
PROCEDURES FOR SYNTHESIS OF HEATER-MULTIMATE POLYPEPTIDES WHEN USING A HAPLOID COUPLE STRATEGY
|
WO2005055944A2
(en)
|
2003-12-05 |
2005-06-23 |
Cincinnati Children's Hospital Medical Center |
Oligosaccharide compositions and use thereof in the treatment of infection
|
KR101297146B1
(ko)
|
2004-05-10 |
2013-08-21 |
마크로제닉스, 인크. |
인간화 FcγRIIB 특이적 항체 및 그의 사용 방법
|
WO2007024249A2
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
EP1674479A1
(en)
*
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
ES2971647T3
(es)
|
2005-04-15 |
2024-06-06 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP1726650A1
(en)
*
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
WO2006138700A2
(en)
*
|
2005-06-17 |
2006-12-28 |
Biorexis Pharmaceutical Corporation |
Anchored transferrin fusion protein libraries
|
CA2615057A1
(en)
*
|
2005-07-12 |
2007-01-18 |
Codon Devices, Inc. |
Compositions and methods for biocatalytic engineering
|
EP1746103A1
(en)
*
|
2005-07-20 |
2007-01-24 |
Applied NanoSystems B.V. |
Bifunctional protein anchors
|
JP5105485B2
(ja)
|
2005-08-10 |
2012-12-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を有する抗体の同定および工学的改変およびその使用方法
|
SG170110A1
(en)
*
|
2006-03-10 |
2011-04-29 |
Macrogenics Inc |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
US20070231805A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Baynes Brian M |
Nucleic acid assembly optimization using clamped mismatch binding proteins
|
EP1918302A3
(en)
*
|
2006-05-18 |
2009-11-18 |
AvantGen, Inc. |
Methods for the identification and the isolation of epitope specific antibodies
|
WO2008105886A2
(en)
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
EP2032159B1
(en)
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
PT2029173T
(pt)
|
2006-06-26 |
2016-11-02 |
Macrogenics Inc |
Anticorpos específicos fc rib e seus métodos de uso
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
US8822639B2
(en)
|
2006-12-12 |
2014-09-02 |
Biorexis Pharmaceutical Corporation |
Transferrin fusion protein libraries
|
AU2008216418A1
(en)
*
|
2007-02-09 |
2008-08-21 |
Medimmune, Llc |
Antibody libray display by yeast cell plasma membrane
|
EP2617827A1
(en)
|
2007-03-26 |
2013-07-24 |
Celexion, LLC |
Method for displaying engineered proteins on a cell surface
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
MX2010002661A
(es)
|
2007-09-14 |
2010-05-20 |
Adimab Inc |
Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
|
US8637435B2
(en)
*
|
2007-11-16 |
2014-01-28 |
Merck Sharp & Dohme Corp. |
Eukaryotic cell display systems
|
CN104645329A
(zh)
|
2007-11-30 |
2015-05-27 |
Abbvie公司 |
蛋白制剂及其制备方法
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
US8795667B2
(en)
*
|
2007-12-19 |
2014-08-05 |
Macrogenics, Inc. |
Compositions for the prevention and treatment of smallpox
|
WO2009111183A1
(en)
*
|
2008-03-03 |
2009-09-11 |
Glycofi, Inc. |
Surface display of recombinant proteins in lower eukaryotes
|
ITUD20080055A1
(it)
*
|
2008-03-13 |
2009-09-14 |
Transactiva S R L |
Procedimento per la produzione di una proteina umana in pianta, in particolare un enzima lisosomiale umano ricombinante in endosperma di cereali
|
AU2009231991B2
(en)
|
2008-04-02 |
2014-09-25 |
Macrogenics, Inc. |
HER2/neu-specific antibodies and methods of using same
|
EP3045475B1
(en)
|
2008-04-02 |
2017-10-04 |
MacroGenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
CA2726845C
(en)
*
|
2008-06-04 |
2017-09-26 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
US8067339B2
(en)
|
2008-07-09 |
2011-11-29 |
Merck Sharp & Dohme Corp. |
Surface display of whole antibodies in eukaryotes
|
MX2011006483A
(es)
|
2008-12-16 |
2011-07-13 |
Novartis Ag |
Sistemas de despliegue en levadura.
|
PT2486141T
(pt)
|
2009-10-07 |
2018-05-09 |
Macrogenics Inc |
Polipéptidos contendo uma região fc que apresenta uma função efectora melhorada, devido a modificações do grau de fucosilação, e métodos para a sua utilização
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
ME03447B
(me)
|
2010-03-04 |
2020-01-20 |
Macrogenics Inc |
Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba
|
KR102024922B1
(ko)
|
2010-07-16 |
2019-09-25 |
아디맵 엘엘씨 |
항체 라이브러리
|
EP2601216B1
(en)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
EP2670779B1
(en)
|
2011-02-01 |
2017-08-02 |
Bac Ip B.V. |
Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies
|
EP2710382B1
(en)
|
2011-05-17 |
2017-10-18 |
Bristol-Myers Squibb Company |
Improved methods for the selection of binding proteins
|
EP2714079B2
(en)
|
2011-05-21 |
2019-08-28 |
MacroGenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
KR20140084253A
(ko)
|
2011-10-24 |
2014-07-04 |
애브비 인코포레이티드 |
Tnf에 대한 면역결합제
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
US9908938B2
(en)
|
2013-03-14 |
2018-03-06 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
CA2963991A1
(en)
|
2014-09-29 |
2016-04-07 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
WO2016176573A1
(en)
|
2015-04-30 |
2016-11-03 |
Board Of Regents, The University Of Texas System |
Antibacterial polypeptide libraries and methods for screening the same
|
US10961311B2
(en)
|
2016-04-15 |
2021-03-30 |
Macrogenics, Inc. |
B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
WO2018104893A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
|